Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

756
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
756
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

36
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
36
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

71
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
71
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

24
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
24

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic power of electrical risk score in acute pulmonary embolism: insights beyond conventional risk stratification.

Heart & lung : the journal of critical care·2026
Same author

Turkish Real-Life Atrial Fibrillation in Clinical Practice: 2-Year Clinical Outcomes of the TRAFFIC Study.

Anatolian journal of cardiology·2025
Same author

Intravenous mitochondrial transplantation as an adjunctive therapy for dilated cardiomyopathy.

Mitochondrion·2025
Same author

Vesicle-guided mitochondria: A new perspective for brain mitochondrial transplantation.

Ageing research reviews·2025
Same author

Periprocedural intermittent contralateral arm ischaemia facilitates radial artery puncture and prevents radial artery spasm.

Cardiovascular journal of Africa·2025
Same author

Biotechnological approaches and therapeutic potential of mitochondria transfer and transplantation.

Nature communications·2025

Related Experiment Video

Updated: Sep 23, 2025

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

918

Long-term Dexamethasone Treatment Increases Cardiac Galectin-3 Levels.

Senay Akin1, Esra Gucuk-Ipek2, Umit Hayta3

  • 1Department of Exercise and Sport Physiology, Faculty of Sport Sciences, Hacettepe University, Ankara, Turkey. senaya@hacettepe.edu.tr.

Cardiovascular Drugs and Therapy
|May 13, 2022
PubMed
Summary

Long-term glucocorticoid use, like dexamethasone, increases cardiac galectin-3 (gal-3) levels in rats. This finding highlights potential risks and informs patient monitoring during prolonged steroid therapy.

Keywords:
Cardiac fibrosisCardiomyocyteGalectin-3Glucocorticoids

More Related Videos

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

3.7K
Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

12.0K

Related Experiment Videos

Last Updated: Sep 23, 2025

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

918
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

3.7K
Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

12.0K

Area of Science:

  • Cardiology
  • Endocrinology
  • Molecular Biology

Background:

  • Glucocorticoids are widely prescribed but can cause cardiac remodeling.
  • Insulin resistance and hypertension are known side effects of glucocorticoids.
  • Galectin-3 (gal-3) is implicated in cardiac remodeling and upregulated by insulin resistance.

Purpose of the Study:

  • To investigate the effect of prolonged glucocorticoid administration on galectin-3 (gal-3) levels in rat myocardium.
  • To determine if gal-3 is associated with cardiac hypertrophy induced by glucocorticoids.

Main Methods:

  • Female Wistar Albino rats were divided into control and dexamethasone-treated groups.
  • Dexamethasone was administered subcutaneously daily for 28 days at 1 mg/kg.
  • Heart weight, body weight, and myocardial gal-3 expression (Western blot) were analyzed.

Main Results:

  • Dexamethasone treatment significantly increased heart weight and heart-to-body weight ratios.
  • A twofold increase in left ventricular galectin-3 expression was observed after 28 days of dexamethasone administration.
  • These changes were statistically significant (p < 0.001).

Conclusions:

  • This study is the first to demonstrate that dexamethasone administration elevates myocardial galectin-3 levels.
  • The findings suggest a link between glucocorticoid use and increased gal-3 in the heart.
  • This research may aid in developing therapeutics and emphasizes monitoring patients on long-term glucocorticoid therapy.